Schaudig K, Wang X, Bouchard C, Hirschberg AL, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ 2024;387:e079525.
PMID: 39557487